MedTrace Logo

Augmenting Flortaucipir Dosimetry Estimates

NCT02336360 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2020-08-11

Study results available
· View outcomes & findings →

Summary

This study will obtain data from urine in subjects administered flortaucipir in an Avid-sponsored study to augment the calculation of radiation dosimetry estimates.

Conditions

Interventions

DRUG

Flortaucipir F18

No flortaucipir administered in this study. Subjects received flortaucipir in an Avid-sponsored study.

Sponsors & Collaborators

  • Avid Radiopharmaceuticals

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2015-06-30
Completion
2015-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02336360 on ClinicalTrials.gov